SPOTLIGHT: No new adverse Tysabri events

Ten months and 10,000 patients after Tysabri was returned to the market for MS, there have been no new occurrences of the lethal infections that triggered its sudden removal in early 2005. Neurologists welcomed the news but said there was still plenty of reason to remain cautious about using the drug. Even after safety questions had been raised about Tysabri, though, many patients had remained committed to the drug due to its high efficacy rate for reducing relapses and disease progression. Report